-
公开(公告)号：US20140288049A1
公开(公告)日：2014-09-25
申请号：US14299497
申请日：2014-06-09
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , C07D401/04 , C07D405/04 , C07D403/04 , C07D471/04 , A61K31/5377 , C07D417/04 , C07D403/06 , C07D403/10 , C07D401/06 , C07D413/06 , A61K31/513 , C07D409/04
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
公开(公告)号：US09873673B2
公开(公告)日：2018-01-23
申请号：US15191943
申请日：2016-06-24
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K31/513 , A61K31/352 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/10 , C07D487/04 , C07D417/04 , C07D471/04 , A61K31/37 , C07D405/06
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
Patent Agency Ranking
公开(公告)号：US20150087585A1
公开(公告)日：2015-03-26
申请号：US14384508
申请日：2013-03-26
Applicant: Pfizer Inc.
Inventor： Kay Ahn , Markus Boehm , Shawn Cabral , Philip A. Carpino , Kentaro Futatsugi , David Hepworth , Daniel W. Kung , Suvi Orr , Jian Wang
IPC: C07D471/04 , A61K45/06 , A61K31/52 , A61K31/5377 , A61K31/538 , C07D487/04 , A61K31/437 , A61K31/506
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/538 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Abstract translation: 抑制二酰基甘油酰基转移酶2（DGAT2）活性的式I的嘌呤衍生物，3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪及其在治疗疾病中的用途 本文描述了与动物相连的动物。
-
公开(公告)号：US20160304469A1
公开(公告)日：2016-10-20
申请号：US15191943
申请日：2016-06-24
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K45/06 , C07D401/04 , C07D405/04 , C07D403/04 , C07D471/04 , C07D409/04 , C07D417/04 , C07D405/10 , C07D405/06 , C07D403/06 , C07D403/10 , C07D401/06 , C07D413/06 , A61K31/5377 , C07D403/12 , A61K31/513
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
公开(公告)号：US09296745B2
公开(公告)日：2016-03-29
申请号：US14384508
申请日：2013-03-26
Applicant: Pfizer Inc.
Inventor： Kay Ahn , Markus Boehm , Shawn Cabral , Philip A. Carpino , Kentaro Futatsugi , David Hepworth , Daniel W. Kung , Suvi Orr , Jian Wang
IPC: C07D471/04 , A61K45/06 , C07D487/04 , C07D519/00 , A61K31/437 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/538
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/538 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Abstract translation: 抑制二酰基甘油酰基转移酶2（DGAT2）活性的式I的嘌呤衍生物，3H-咪唑并[4,5-b]嘧啶和1H-咪唑并[4,5-d]吡嗪及其在治疗疾病中的用途 本文描述了与动物相连的动物。
-
公开(公告)号：US09399626B2
公开(公告)日：2016-07-26
申请号：US14299497
申请日：2014-06-09
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K31/513 , A61K31/352 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/10 , C07D487/04 , C07D417/04 , C07D471/04 , A61K31/37
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Abstract translation: 髓过氧化物酶抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于治疗例如心血管病症的用途。
-
公开(公告)号：US20130296351A1
公开(公告)日：2013-11-07
申请号：US13875604
申请日：2013-05-02
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K45/06 , A61K31/513
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Abstract translation: 髓过氧化物酶抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于治疗例如心血管病症的用途。
-
-
-
-
-
-
Search Results
7
records
(took 0.024 seconds)
